153 related articles for article (PubMed ID: 26360587)
1. Combination cannabinoid and opioid receptor antagonists improves metabolic outcomes in obese mice.
Lockie SH; Stefanidis A; Tschöp MH; Oldfield BJ
Mol Cell Endocrinol; 2015 Dec; 417():10-9. PubMed ID: 26360587
[TBL] [Abstract][Full Text] [Related]
2. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
5. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
[TBL] [Abstract][Full Text] [Related]
7. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
8. Does rimonabant independently affect free fatty acid and glucose metabolism?
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
[TBL] [Abstract][Full Text] [Related]
9. Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
Heppenstall C; Bunce S; Smith JC
Nutr J; 2012 Jul; 11():50. PubMed ID: 22824101
[TBL] [Abstract][Full Text] [Related]
10. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
11. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
[TBL] [Abstract][Full Text] [Related]
12. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
[TBL] [Abstract][Full Text] [Related]
13. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
15. Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.
Wright FL; Rodgers RJ
Psychopharmacology (Berl); 2013 Mar; 226(2):415-31. PubMed ID: 23142959
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats.
Tallett AJ; Blundell JE; Rodgers RJ
Pharmacol Biochem Behav; 2009 Jan; 91(3):358-66. PubMed ID: 18755211
[TBL] [Abstract][Full Text] [Related]
17. Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus.
Rorato R; Miyahara C; Antunes-Rodrigues J; Elias LL
Regul Pept; 2013 Mar; 182():12-8. PubMed ID: 23327999
[TBL] [Abstract][Full Text] [Related]
18. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
[TBL] [Abstract][Full Text] [Related]
19. Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching.
Tallett AJ; Blundell JE; Rodgers RJ
Physiol Behav; 2008 Jun; 94(3):422-31. PubMed ID: 18394662
[TBL] [Abstract][Full Text] [Related]
20. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]